HIV research

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 stockanalysis.com stockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47% ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same period ts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects

18 October 2025

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Stock Jumps as Outlook Brightens Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share benzinga.com. Year-to-date, the stock has rallied nearly 47%, adding tens of billions to Gilead’s market value stockanalysis.com. This far outpaces the single-digit gain of the Nasdaq Biotechnology Index over the same period stockanalysis.com invesco.com. Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects. Notably, Gilead’s Q2 results in August beat expectations and prompted management to raise

17 October 2025

Analyst Ratings · Biotechnology · HIV Research · Patent News · Stock Market